Julia A. Beaver

Biochemistry, Genetics and Molecular BiologyMedicineEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 23 papers. Top paper: “FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations”.

FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3713

N/A

1.7DataRank · unranked

58 citations

Erin Larkins, Somak Chatterjee, Pallavi S. Mishra‐Kalyani, Stephanie Aungst, Emily Wearne +13 more

FDA Approval Summary: Mobocertinib for Metastatic Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2072

N/A

1.7DataRank · unranked

42 citations

Liza Stapleford, Nicole Drezner, Anup Amatya, Pallavi S. Mishra‐Kalyani, Yuan Li Shen +22 more

FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1270

N/A

1.2DataRank · unranked

46 citations

Diana Bradford, Xiaoxue Li, Pallavi S. Mishra‐Kalyani, Yuan Li Shen, Lingshan Wang +14 more

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0327

N/A

0DataRank · unranked

580 citations

Lola A. Fashoyin‐Aje, Martha Donoghue, Mengdie Yuan, Lisa Rodríguez, Pamela Gallagher +7 more

FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-3074

N/A

0DataRank · unranked

309 citations

Nicole Drezner, Xiaoxue Li, Pallavi S. Mishra‐Kalyani, Yajun Liu, Hong Zhao +11 more

FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4557

N/A

0DataRank · unranked

164 citations

Christy Osgood, Harpreet Singh, Haw-Jyh Chiu, Tiffany K. Ricks, Edwin C.Y. Chow +14 more

U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2600

N/A

0DataRank · unranked

72 citations

Preeti Narayan, Christy Osgood, Suparna Wedam, Tatiana M. Prowell, Jennifer Gao +17 more

FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1466

N/A

0DataRank · unranked

59 citations

Paz J. Vellanki, Erin Larkins, Somak Chatterjee, Pallavi S. Mishra-Kalyani, Youwei Bi +11 more

FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non–small Cell Lung Cancer, A Collaborative Project Orbis Review

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4338

N/A

0DataRank · unranked

57 citations

Flora Mulkey, Adnan A. Jaigirdar, Lisa Rodríguez, Yibo Wang, Yuan Xu +14 more

FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2334

N/A

0DataRank · unranked

45 citations

Chana Weinstock, Lijun Zhang, Mallorie H. Fiero, Miao Zhao, Eias Zahalka +14 more

FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-3247

N/A

0DataRank · unranked

39 citations

Christy Osgood, Anup Amatya, Mallorie H. Fiero, C.J. George Chang, Tiffany K. Ricks +32 more

Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4912

N/A

0DataRank · unranked

29 citations

Mallorie H. Fiero, Erik Bloomquist, A. K. Sinha, Steven J. Lemery, Harpreet Singh +13 more

U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2599

N/A

0DataRank · unranked

23 citations

Preeti Narayan, Gwynn Ison, Tara Berman, Daniel L. Suzman, Suparna Wedam +18 more

The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4429

N/A

0DataRank · unranked

4 citations

Yutao Gong, Kirsten B. Goldberg, Paul G. Kluetz, Marc R. Theoret, Laleh Amiri‐Kordestani +13 more

FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated Tumors

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1054

N/A

0DataRank · unranked

175 citations

Michael H. Brave, Chana Weinstock, Gautam U. Mehta, Diana Bradford, Haley Gittleman +17 more

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4462

N/A

0DataRank · unranked

64 citations

Shan Pradhan, Lola A. Fashoyin‐Aje, Yi Ren, Yuan-Li Shen, Yuan Xu +12 more

FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0873

N/A

0DataRank · unranked

48 citations

Amy Barone, Somak Chatterjee, Pallavi S. Mishra‐Kalyani, Yuan Li Shen, Emasenyie Isikwei +14 more

FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0617

N/A

0DataRank · unranked

10 citations

Sandra J. Casak, Pallavi S. Mishra‐Kalyani, Pourab Roy, Julia A. Beaver, Richard Pazdur +4 more

FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3699

N/A

0DataRank · unranked

47 citations

Erin Larkins, A. K. Sinha, Pallavi S. Mishra‐Kalyani, Samina Jafri, Shyam Kalavar +6 more

FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-3652

N/A

0DataRank · unranked

169 citations

Tatiana M. Prowell, Jennifer Gao, Laura L. Fernandes, Emily Li, Xiling Jiang +29 more

Evaluation of somatic copy number variation detection by NGS technologies and bioinformatics tools on a hyper-diploid cancer genome

Genome biology(2024)10.1186/s13059-024-03294-8

N/A

0DataRank · unranked

40 citations

Luyao Ren, Cu Nguyen, Francesco Brundu, Lily Zheng, Yongmei Zhao +21 more

Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-0834

N/A

0DataRank · unranked

104 citations

Flora Mulkey, Emma Scott, Ashley F. Ward, Donna Przepiorka, Rosane Charlab +9 more

FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-3901

N/A

0DataRank · unranked

101 citations

Adnan A. Jaigirdar, Flora Mulkey, Joyce Cheng, Salaheldin S. Hamed, Yangbing Li +16 more